To:


Yissum
Research Development Company


of
the Hebrew University of Jerusalem


Edmond
Safra Campus,


Givat
Ram, POB 39135


Jerusalem
91390


Israel


 


Re: Fourth
Extension of Agreement for rendering of Services


 


We
do hereby refer to the Agreement for the Rendering of Services dated as of June 20, 2005 (the "Service Agreement") and
the extension thereto dated as of June, 20 2006 ("Extension of Agreement for Rendering of
Services") and the second extension thereto dated as of December 19, 2006 ("Second Extension of Agreement for Rendering
of Services ")and the third extension thereto dated as of June 17, 2007 (collectively,
the "Extended Service Agreements") and the License Agreement dated November 27th, 2002 (the "License
Agreement") all executed by and between Yissum Research Development Company of the Hebrew University of Jerusalem ("Yissum")
and Morria Biopharmaceuticals, Inc. (the "Company").


 


Unless
the context otherwise requires, all capitalized terms used herein shall have the meaning ascribed to them in the Service
Agreement.


 


The
Company does hereby request that, further to Yissum tasks and services pursuant to the Extended Service Agreements, and fully completed
and performed by Yissum,Yissum performs the additional tasks and services set forth on Appendix A hereto (the "Additional
Services"). All of such Additional Services shall be included in the scope of the definition of Services under the Service
Agreement, and shall be performed in accordance with the timetable set forth on Appendix A hereto. In consideration, the Company
shall pay Yissum an additional amount including overhead, of $ 60,000 (all inclusive) (the "Additional Service Fee").
The Additional Service Fee is payable as follows: in quarterly payments starting from June 1, 2008 and ending on June 1, 2009 according
to the following schedule:


i.$
10,000 within fourteen (14) days of signing this Agreement.


ii.$
15,000 on September 1, 2008.


iii.$
15,000 on December 1, 2008 and


iv.$
20,000 on March 1, 2009.


 



    	 



    	 



    

 


All
terms and conditions as set out in the Service Agreement shall apply mutatis mutandis
in respect of the Additional Service Fee and the Additional Services as defined under this Fourth Extension of Agreement for Rendering
of Services, including without limitation, the extension of the right and license to the Company of the Service Agreement Results,
such to include the Additional Services (as defined herein).


 


Your Signature on this
copy of the document shall constitute your approval and agreement to all that is written herein.


 


	MORRIA BIOPHARMACEUTICALS PLC.	 
	/s/ YUVAL COHEN	 	 
	By: Yuval Cohen	 	Date: June 2, 2008
	 	 	 
	Title: President	 	 
	 	 	 
	We hereby agree and approve:	 	 
	/s/ ELENA CANETTI	 	 
	 	 	 
	By: Elena Canetti	 	Date: June, 2 2008
	Title: VP Scientific Services Yissum	 	 
	 	 	 
	/s/ NAVA SWERSKY SOFER	 	 
	By: Nava Swersky Sofer	 	Date: June, 2 2008
	Title: CEO Yissum	 	 


 



    	 



    	 



    

 


APPENDIX A


 


May 4th, 2008


 


Research Program for
Morria Biopharmaceuticals Plc


 


Proposed by Prof. Saul Yedgar
of the Dept of Biochemistry, Hebrew University Medical School, Jerusalem


 


Aim


 


Exploring mechanisms of inflammatory
processes and the therapeutic potential of MFAIDs in in vitro and
in vivo models.


 


Scope


 


Exploration of inflammatory mechanisms
and their control in in vitro and in vivo experimental systems.


 


Testing of MFAID candidates for
their potential in treating inflammatory /allergic conditions: intestinal inflammation (IBD), osteoarthritis, cancer, asthma, skin
inflammation, eye inflammation, viral infections and CNS and the like.


 


Continuing the chemical characterization
and optimization of MFAIDs.


 


Setting up new in vivo
and in vitro models for testing MFAIDs on inflammatory/allergic
diseases.


 


Outcomes


 


		·	Data on efficacy of various MFAIDs in the above-mentioned disease fields.
	 	 	 



		·	Optimization of selected MFAID synthesis,



 


Research Period: 12 months:
June 1st, 2008 - June 30th, 2009.


 


Budget: $60,000.־
(including overhead) to be paid in quarterly payments.


 








    	3